Results of qualitative test on fatty acid binding cardiac protein in suspected acute coronary syndrome and various kidney function level
https://doi.org/10.15829/1560-4071-2018-9-28-32
Abstract
Aim. To evaluate diagnostic properties of qualitative tests for cardiac fraction of the fatty acid binding protein (cFABP) in patients hospitalized with suspected acute coronary syndrome (ACS), depending on glomerular filtration rate (GFR) level.
Material and methods. Totally, 465 patients included, admitted with ACS within 24 hours from onset. All patients underwent cFABP test with immune chromatographic express tests “CardioFABP” (Novosibirsk, Russia) and/or “CARD-INFO” (Obninsk, Russia), as the levels of serum creatinine with further GFR calculation. Assessment of diagnostic characteristics was done by the values of specificity, sensitivity, and diagnostic correctness, as well as overall positive and negative test results according to GFR.
Results. The analysis did not reveal significant difference in the number of positive and negative results of cFABP with the “CARD-INFO” (χ2=6,822, р=0,146), “CardioFABP” 10 ng/mL (χ2=4,968, р=0,291) and “CardioFABP” 15 ng/mL (χ2=8,673, р=0,07) in comparison by GFR. With coupled comparison, in the groups of patients by GFR there were differences in specificity for “CARD-INFO” (Fischer criteria =0,017, р˂0,05) and precision for “CardioFABP” (10 ng/mL) (χ2=5,793, р=0,017) in patients by GFR levels 60-90 and 30-59 mL/min/1,73 m2. For the other parameters of diagnostical efficacy there were no differences by GFR. In severe renal dysfunction (GFR ˂15 mL/min/1,73 m2) results of qualitative cFABP were false positive in 10 cases among 11 (90,9%).
Conclusion. In patients hospitalized for suspected ACS, the results and diagnostic characteristics of the express-tests for cFABP “CARD-INFO” and “CardioFABP” depended mildly on GFR level with its values ≥15 mL/min/1,73 m2. Low number of patients with GFR ˂15 mL/min/1,73 m2 made not possible to acquire significant data on cFABP in this category of patients, however the data available make it not to apply the test in this category of patients.
About the Authors
V. A. KokorinRussian Federation
Moscow, PhD
Competing Interests: No conflicts of interest
E. A. Kochmareva
Russian Federation
Competing Interests: No conflicts of interest
M. N. Arefiev
Russian Federation
Competing Interests: No conflicts of interest
I. G. Gordeev
Russian Federation
Moscow
Competing Interests: No conflicts of interest
References
1. El Missiri A, Okasha N, Badr T. Heart-type fatty acid-binding protein detects more patients with non-ST segment elevation myocardial infarction compared to troponin-T. Egypt Heart J. 2016;68(1):11-6. doi:10.1016/j.ehj.2015.09.002.
2. McCann CJ, Glover BM, Menown IB, et al. Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T. Eur Heart J. 2008;29(23):284350. doi:10.1093/eurheartj/ehn363.
3. Pyati AK, Devaranavadagi BB, Sajjannar SL, et al. Heart-type fatty acid binding protein: a better cardiac biomarker than CK-MB and myoglobin in the early diagnosis of acute myocardial infarction. J Clin Diagn Res. 2015;9(10):BC08-11. doi:10.7860/JCDR/2015/15132.6684.
4. Hamm CW, Bassand J-P, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2011;32:2999-3054. doi:10.1093/eurheartj/ehr236.
5. Konstantinides SV, Torbicki A, Agnelli G, et al. Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35:3033-80. doi:10.1093/eurheartj/ehu283.
6. Kalinichenko RM, Kopylov FYu, Syrkin AL, et al. The results of application of the rapid quantitative assay for fatty acid-binding protein at the onset of acute coronary syndrome. Klinicheskaya Meditsina. 2013;1:32-7. (In Russ.)
7. Kokorin VA, Goncharov AP, Goncharova AYa, et al. Effectiveness of the new qualitative express-test for evaluation of heart type fatty acid binding protein in the differential diagnosis of myocardial infarction. Kazan medical school diary. 2017;4(18):49-53. (In Russ.)
8. Martynov AI, Voevoda MI, Arutyunov GP, et al. Clinical effectiveness of early acute myocardial infarction diagnostics, based on the assessment of cardiac fatty acid binding protein levels. Russ J Cardiol. 2012;18(3):7-11. (In Russ.) doi:10.15829/1560-4071-2012-3-7-11.
9. Plavunov NF, Kadyshev VA, Sokolov AYu, et al. Approbation of the express-test “CardioFABP” in practice of the emergency medical service for the differential diagnosis of acute coronary syndrome. Emergency medical care. 2014;4:31-6. (In Russ.) doi:10.24884/20726716-2014-15-4-31-36.
10. Kleine AH, Glatz JF, van Nieuwenhoven FA, et al. Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man. Mol Cell Biochem. 1992;116:155-62. doi:10.1007/bf01270583.
11. Gorski J, Hermens WT, Borawski J, et al. Increased fatty acid-binding protein concentration in plasma of patients with chronic renal failure. Clin Chem. 1997;43(1):193-5.
12. Nayashida N, Chihara S, Tayama E, et al. Influence of renal function on serum and urinary heart fatty acid-binding protein levels. J Cardiovasc Surg. 2001;42(6):735-40.
13. Al-Hadi HA, William B, Fox KA. Serum level of heart-type fatty acid-binding protein in patients with chronic renal failure. Sultan Qaboos Univ Med J. 2009;9(3):311-4. doi:10.18295/squmj.
Review
For citations:
Kokorin V.A., Kochmareva E.A., Arefiev M.N., Gordeev I.G. Results of qualitative test on fatty acid binding cardiac protein in suspected acute coronary syndrome and various kidney function level. Russian Journal of Cardiology. 2018;(9):28-32. (In Russ.) https://doi.org/10.15829/1560-4071-2018-9-28-32